<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Recently I attended CU Anschutz’s Sickle Cell Summit and learned of new therapeutic modalities — pharmacologic as well as the exciting CRISPR/Cas9 gene editing therapy. Unfortunately, many people who have SCT are unaware of their status or the implications of SCD their offspring might inherit. Such knowledge can be useful in determining future family planning. On a positive note, the Anschutz Sickle Cell Group under Dr. Kathryn Hassell as well as Colorado Sickle Cell Association are actively disseminating information on SCT.